APA (7th ed.) Citation

Seohyun Son, Ahmed Elkamhawy, Anam Rana Gul, Ahmed A. Al‐Karmalawy, Radwan Alnajjar, Ahmed Abdeen, . . . Kyeong Lee. (2023). Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Seohyun Son, et al. Development of New TAK-285 Derivatives as Potent EGFR/HER2 Inhibitors Possessing Antiproliferative Effects Against 22RV1 and PC3 Prostate Carcinoma Cell Lines. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Seohyun Son, et al. Development of New TAK-285 Derivatives as Potent EGFR/HER2 Inhibitors Possessing Antiproliferative Effects Against 22RV1 and PC3 Prostate Carcinoma Cell Lines. Taylor & Francis Group, 2023.